Ultimately, the examination of CD44-targeted functionalized nanocarriers in relation to other targeted therapeutics for NSCLC therapy highlights their distinct characteristics, possible collaborations, and obstacles (127). Here, CD44 is linked to non-small cell lung carcinoma.